JP2025510912A5 - - Google Patents

Info

Publication number
JP2025510912A5
JP2025510912A5 JP2024557191A JP2024557191A JP2025510912A5 JP 2025510912 A5 JP2025510912 A5 JP 2025510912A5 JP 2024557191 A JP2024557191 A JP 2024557191A JP 2024557191 A JP2024557191 A JP 2024557191A JP 2025510912 A5 JP2025510912 A5 JP 2025510912A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
dmt
meo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510912A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057842 external-priority patent/WO2023186806A1/en
Publication of JP2025510912A publication Critical patent/JP2025510912A/ja
Publication of JP2025510912A5 publication Critical patent/JP2025510912A5/ja
Pending legal-status Critical Current

Links

JP2024557191A 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン Pending JP2025510912A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000083.0 2022-03-27
EP22000086 2022-03-27
EP22000086.3 2022-03-27
EP22000083 2022-03-27
EP23153995.8 2023-01-30
EP23153939 2023-01-30
EP23153995 2023-01-30
EP23153939.6 2023-01-30
PCT/EP2023/057842 WO2023186806A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder

Publications (2)

Publication Number Publication Date
JP2025510912A JP2025510912A (ja) 2025-04-15
JP2025510912A5 true JP2025510912A5 (enExample) 2026-04-10

Family

ID=86007166

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療

Country Status (9)

Country Link
US (9) US20250241893A1 (enExample)
EP (7) EP4499088A1 (enExample)
JP (6) JP2025510912A (enExample)
KR (6) KR20250005183A (enExample)
CN (2) CN119095595A (enExample)
AU (6) AU2023246774A1 (enExample)
CA (6) CA3255348A1 (enExample)
IL (6) IL315899A (enExample)
WO (9) WO2023186820A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
HUE069534T2 (hu) * 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
WO2021216489A1 (en) * 2020-04-20 2021-10-28 Lobe Sciences Ltd. Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20240299353A1 (en) 2021-03-12 2024-09-12 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt

Similar Documents

Publication Publication Date Title
JP2025510912A5 (enExample)
JP2025510913A5 (enExample)
JP2025510369A5 (enExample)
JP2025511081A5 (enExample)
JP2025510368A5 (enExample)
JP2025512831A5 (enExample)
JP2025510916A5 (enExample)
JP2025510295A5 (enExample)
JP2025511084A5 (enExample)
Wilson et al. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home.
JP2021527092A5 (enExample)
JP2025510296A5 (enExample)
JP2025510914A5 (enExample)
Roberts et al. Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure
JP2020532531A5 (enExample)
JP2022514645A5 (enExample)
CN113891722A (zh) 用于漏服剂量的花生口服免疫疗法给药计划表
AU2016378478B2 (en) Treatment of moderate to severe influenza
Blumer et al. Effect of sedation with midazolam and time to discharge among pediatric dental patients
TW201320994A (zh) 投藥療程
JP2025511072A5 (enExample)
CN105412118A (zh) 治疗急慢性呼吸困难的西药组合物及其制备方法
JP2025510915A5 (enExample)
Lamas-Aguilar et al. Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review
Moore et al. Trial of reserpine in treatment of schizophrenia